XIENCE

Patients treated with XIENCE V in SPIRIT III trial experience better long-term clinical outcomes, lower rates of stent thrombosis than patients treated with TAXUS.

Patients get POWERFUL – eHEALTH Team

[This article was published in the February 2008 issue of the eHEALTH Magazine (https://www.ehealthonline.org)]

In a recent ruling of the Supreme Court, prior consent of patients have been made mandatory for all surgical procedures, unless in critical medical conditions

Cirrius Wireless designs marketing network for pharma giant

Pharmaceutical firm Merck Ltd announced recently that it has partnered with software firm Cirrius Wireless Technologies for providing mobile-based solution, marketing network and activation system (MANAS) to its sales representatives across the country.

Cellworks in collaboration with Orchid on drug discovery

Cellworks Research India, the Bangalore-based research and development (R&D) wing of Cellworks Group Inc (California-headquartered company), has assisted Chennai-based Orchid Chemicals and Pharmaceuticals by providing system biology technology in carrying out ongoing New Chemical Entity (NCE) research programme.

India’s Drug Regulatory Authority to be based on US FDA Model

In the next three years, India would move towards setting up a drug regulatory authority on the model of the US FDA, the country

Govt brings out Indian Pharmacopoeia, 2007

In an effort to control the quality of medicinal products, the government has brought out the Indian Pharmacopoeia, 2007, which lays down the standards for drugs produced or marketed in India.

CRAMS to global pharma companies, give good returns

The pharma sector may have underperformed in the Sensex , but companies providing contract research and manufacturing services (CRAMS) to global pharma companies have given good returns.

IBM targets multi-billion $ health sector in India

IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.

IBM targets multi-billion $ health sector in India

IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.

IBM targets multi-billion $ health sector in India

IBM is targeting multi-billion dollar health business opportunities in India. The company has plans to tap opportunities worth $1 billion each in the Indian pharmaceuticals and health service segments over the next 3-4 years.

Ranbaxy may dilute 60% in new R&D unit

Ranbaxy Laboratories may dilute up to 60% stake in its new research company, which will be formed by hiving off its R&D unit into a separate entity in 2008.

NPIL, Merck in research deal for cancer drugs

Nicholas Piramal (NPIL) has reportedly signed a research deal potentially worth a maximum revenue of USD 350 million with US pharmaceutical giant Merck & Co to carry out early discovery and development of two new cancer drugs, the two companies said on Monday.

India’s Manipal AcuNova acquires German firm Ecron

Clinical research firm Manipal AcuNova Ltd recently announced it has completed the acquisition of ECRON GmbH, Europe.